Citations

Clear

626 citation(s) found for "Mehta, SH".

Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation
Sandoval, Yader , Lewis, Bradley R., Mehta, Ramila A. , Ola, Olatunde , Knott, Jonathan D , Michieli, Laura De , Akula, Ashok , Lobo, Ronstan , Gharacholou, S. Michael , Dworak, Marshall , Crockford, Erika, Rastas, Nicholas, Grube, Eric , Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Lewis, Bradley R , De Michieli, Laura , Dworak, Marshall , Gulati, Rajiv , Jaffe, Allan S. , Yang, Eric H. , Grube, Eric

Mayo Clinic

Circulation | May 10, 2022 | Volume: 145 | Issue: 23 | Pages: 1708-1719

10.1161/circulationaha.122.059235 | PMID 35535607 Get It

Background: There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection of 5 ng/L to exclude acute myocardial infarction. Per the US Food and Drug Administration, hs-cTnT can only report to the limit of quantitation of 6 ng/L, a threshold for which there are limited data. Our goal was to determine whether a single hs-cTnT below the limit of quantitation of 6 ng/L is a safe strategy to identify patients at low risk for acute myocardial injury and infarction. Methods: The efficacy (proportion identified as low risk based on baseline hs-cTnT<6 ng/L) of identifying low-risk patients was examined in a multicenter (n=22 sites) US cohort study of emergency department patients undergoing at least 1 hs-cTnT (CV Data Mart Biomarker cohort). We then determined the performance of a single hs-cTnT<6 ng/L (biomarker alone) to exclude acute myocardial injury (subsequent hs-cTnT >99th percentile in those with an initial hs-cTnT<6 ng/L). The clinically intended rule-out strategy combining a nonischemic ECG with a baseline hs-cTnT<6 ng/L was subsequently tested in an adjudicated cohort in which the diagnostic performance for ruling out acute myocardial infarction and safety (myocardial infarction or death at 30 days) were evaluated. Results: A total of 85 610 patients were evaluated in the CV Data Mart Biomarker cohort, among which 24 646 (29%) had a baseline hs-cTnT<6 ng/L. Women were more likely than men to have hs-cTnT<6 ng/L (38% versus 20%, P <0.0001). Among 11 962 patients with baseline hs-cTnT<6 ng/L and serial measurements, only 1.2% developed acute myocardial injury, resulting in a negative predictive value of 98.8% (95% CI, 98.6–99.0) and sensitivity of 99.6% (95% CI, 99.5–99.6). In the adjudicated cohort, a nonischemic ECG with hs-cTnT<6 ng/L identified 33% of patients (610/1849) as low risk and resulted in a negative predictive value and sensitivity of 100% and a 30-day rate of 0.2% for myocardial infarction or death. Conclusions: A single hs-cTnT below the limit of quantitation of 6 ng/L is a safe and rapid method to identify a substantial number of patients at very low risk for acute myocardial injury and infarction.
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer, Ayal A. , Lamba, Nayan , Ahluwalia, Manmeet S. , Aldape, Kenneth , Boire, Adrienne , Brown, Paul D. , Camidge, D. Ross , Chiang, Veronica , Davies, Michael A. , Hu, Leland , Huang, Raymond Y. , Kumthekar, Priya , Lam, Keng , Lee, Eudocia Q. , Parsons, Michael , Reardon, David A. , Sheehan, Jason P. , Tawbi, Hussein A. , Weller, Michael , Wen, Patrick Y. , Kaufmann, Timothy, Kumthekar, Priya , Parsons, Michael W , Soffietti, Riccardo , Tawbi, Hussein , Weller, Michael , Ahluwalia, Manmeet S , Huang, Raymond , Brastianos, Priscilla K. , Kaufmann, Timothy J. , Lin, Nancy U. , Mehta, Minesh P. , Soffietti, Riccardo , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | May 3, 2022 | Volume: 24 | Issue: 10 | Pages: 1613-1646

10.1093/neuonc/noac118 | PMID 35762249 Get It

Abstract Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is known about brain metastases than cancer-related entities of similar incidence. Advances in oncologic care have heightened the importance of intracranial management. Here, in this consensus review supported by the Society for Neuro-Oncology (SNO), we review the landscape of brain metastases with particular attention to management approaches and ongoing efforts with potential to shape future paradigms of care. Each coauthor carried an area of expertise within the field of brain metastases and initially composed, edited, or reviewed their specific subsection of interest. After each subsection was accordingly written, multiple drafts of the manuscript were circulated to the entire list of authors for group discussion and feedback. The hope is that the these consensus guidelines will accelerate progress in the understanding and management of patients with brain metastases, and highlight key areas in need of further exploration that will lead to dedicated trials and other research investigations designed to advance the field.
Effect of olfactory bulb pathology on olfactory function in normal aging
Tremblay, Cécilia , Intorcia, Anthony J., Sue, Lucia I., Wilson, Jeffrey R. , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Adler, Charles H. , Driver‐Dunckley, Erika

Mayo Clinic

Brain Pathology | April 29, 2022 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/bpa.13075 | PMID 35485279 Get It

AbstractDecline of olfactory function is frequently observed in aging and is an early symptom of neurodegenerative diseases. As the olfactory bulb (OB) is one of the first regions involved by pathology and may represent an early disease stage, we specifically aimed to evaluate the contribution of OB pathology to olfactory decline in cognitively normal aged individuals without parkinsonism or dementia. This clinicopathological study correlates OB tau, amyloid β (Aβ) and α‐synuclein (αSyn) pathology densities and whole brain pathology load to olfactory identification function as measured with the University of Pennsylvania Smell Identification Test (UPSIT) and clinical data measured proximate to death in a large autopsy study including 138 cases considered non‐demented controls during life. Tau pathology was frequently observed in the OB (95% of cases), while both Aβ (27% of cases) and αSyn (20% of cases) OB pathologies were less commonly observed. A weak correlation was only observed between OB tau and olfactory performance, but when controlled for age, neither OB tau, Aβ or αSyn significantly predict olfactory performance. Moreover, whole brain tau and αSyn pathology loads predicted olfactory performance; however, only αSyn pathology loads survived age correction. In conclusion, OB tau pathology is frequently observed in normally aging individuals and increases with age but does not appear to independently contribute to age‐related olfactory impairment suggesting that further involvement of the brain seems necessary to contribute to age‐related olfactory decline.
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
Borlaug, Barry A. , Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Daniel , Bruch, Leonhard , Celermajer, David S. , Claggett, Brian , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Gustafsson, Finn , Heyden, Jan van der, Hasenfuß, Gerd, Hummel, Scott L. , Komtebedde, Jan, Mazurek, Jeremy A., McKenzie, Scott , Mehta, Shamir R. , Petrie, Mark C. , Post, Marco C., Nair, Ajith, Rieth, Andreas , Silvestry, Frank E., Solomon, Scott D. , Trochu, Jean‐Noël , Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II, Bugger, Heiko , Nair, Ajith , Burkhoff, Daniel , Hayward, Chris , Hummel, Scott L , Kaye, David M , Massaro, Joseph M. , McKenzie, Scott , Mehta, Shamir R , Petrie, Mark C , Rieth, Andreas , Solomon, Scott David , Trochu, Jean-Noël , Shah, Sanjiv J , Borlaug, Barry A , Nair, Ajith P , Celermajer, David , Gustafsson, Finn , Blair, John, Bergmann, Martin W., Bruch, Leonhard , Claggett, Brian L , Cleland, John G.F., Cutlip, Donald E. , Dauber, Ira, Eicher, Jean-Christophe , Gao, Qi, Gorter, Thomas M. , Heyden, Jan van der, Hasenfuß, Gerd, Komtebedde, Jan, Mazurek, Jeremy A., Post, Marco C., Nair, Ajith, Silvestry, Frank E., Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Investigators, on behalf of the REDUCE LAP-HF-II

Mayo Clinic

Circulation | March 31, 2022 | Volume: 145 | Issue: 21 | Pages: 1592-1604

10.1161/circulationaha.122.059486 | PMID 35354306 Get It

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome—a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status—was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004). Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.
Canagliflozin-associated severe hyponatremia: a rare and potentially adverse effect?
Dhanasekaran, Maheswaran , Narayanan, Siddharth , Mehta, Suchita, Mastoris, Ioannis

Mayo Clinic

Endocrinology, Diabetes & Metabolism Case Reports | March 30, 2022 | Volume: 2022 | Issue: No issue available | Pages: No page available

10.1530/edm-21-0035 | PMID 35352682 Get It

Summary Sodium-glucose cotransporter-2 inhibitors (SGLT2i) induce osmotic diuresis by inhibiting the proximal renal tubular reabsorption of the filtered glucose load, which in turn can occasionally lead to severe dehydration and hypotension amidst other adverse effects. We present a case of a 49-year-old man with type 2 diabetes mellitus (T2D) on canagliflozin, a SGLT2i. The patient was brought to the emergency room following a motor vehicle accident. He was confused and had an altered mental status. His blood alcohol and urine toxicology screens were negative. Initial investigations revealed that he had severe hyponatremia with euglycemic ketoacidosis. The adverse condition was reversed with close monitoring and timely management, and the patient was eventually discharged. This is the first report to suggest hyponatremia as a potentially serious adverse effect following SGLT2i therapy. Its impact on the renal tubule handling of sodium and water is not yet well characterized. While further studies are warranted to understand better the pathophysiological mechanisms associated with SGLT2i-induced adverse effects, timely dose reduction or perhaps even its temporary discontinuation may be recommended to prevent complications. Learning points Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are usually well-tolerated, but some serious adverse effects have been documented. Our case report suggests hyponatremia as a potential, rare side effect of SGLT2i and makes physicians aware of the occurrence of such life-threatening but preventable complications. Timely and close monitoring of the patient, with temporary discontinuation of this drug, may be recommended towards effective management. Studies demonstrating a comprehensive understanding of SGLT2i-related electrolyte derangements are warranted.
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
Spikes, Leslie , Eggert, Michael, Johri, Shilpa , Joly, Joanna M., Mehta, J.P. , Palevsky, Harold I. , Ramani, Gautam , Restrepo‐Jaramillo, Ricardo, Sahay, Sandeep , Shah, Trushil , Miceli, Melissa, Smith, Peter , Shapiro, Shelley, Spikes, Leslie A , Sahay, Sandeep , Bajwa, Abubakr A. , Burger, Charles D. , Desai, Sapna V., El‐Kersh, Karim , Fisher, Micah R., Deng, Chunqin

Mayo Clinic

Pulmonary Circulation | March 23, 2022 | Volume: 12 | Issue: 2 | Pages: No page available

10.1002/pul2.12063 | PMID 35514770 Get It

AbstractInhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment for nebulizer preparation, maintenance, and treatment. A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil inhalation solution. Fifty‐one patients on a stable dose of treprostinil inhalation solution enrolled and transitioned to TreT at a corresponding dose. Six‐minute walk distance (6MWD), device preference and satisfaction (Preference Questionnaire for Inhaled Treprostinil Devices [PQ‐ITD]), PAH Symptoms and Impact (PAH‐SYMPACT®) questionnaire, and systemic exposure and pharmacokinetics for up to 5 h were assessed at baseline for treprostinil inhalation solution and at Week 3 for TreT. Adverse events (AEs) were consistent with studies of inhaled treprostinil in patients with PAH, and there were no study drug‐related serious AEs. Statistically significant improvements occurred in 6MWD, PQ‐ITD, and PAH‐SYMPACT. Forty‐nine patients completed the 3‐week treatment phase and all elected to participate in an optional extension phase. These results demonstrate that, in patients with PAH, transition from treprostinil inhalation solution to TreT is safe, well‐tolerated, and accompanied by statistically significant improvements in key clinical assessments and patient‐reported outcomes with comparable systemic exposure between the two formulations at evaluated doses (trial registration: clinicaltrials.gov identifier: NCT03950739).
The Effects of Obesity and Bariatric Surgery on Rates of Upper Extremity Compression Neuropathies
Maasarani, Samantha , Thomson, Kyle B. , Becerra, Adán Z. , Adogwa, Owoicho , Mehta, Ankit I. , Noland, Shelley S. , Torquati, Alfonso , Pires, Giovanna R, Khalid, Syed , Pires, Giovanna Rodosli

Mayo Clinic

Annals of Surgery Open | March 16, 2022 | Volume: 3 | Issue: 1 | Pages: e146

10.1097/as9.0000000000000146 | PMID 37600109 Get It

Objectives: To estimate the effects of obesity on all types of upper extremity compression neuropathies (UECN) (carpal tunnel syndrome and other median nerve, radial nerve, and ulnar nerve compression neuropathies) and to assess whether bariatric surgery modifies these effects. Background: UECN are increasingly prevalent and decrease the quality of life of affected individuals. Studies suggest obesity as a risk factor for carpal tunnel syndrome, the most common type of UECN. Methods: A retrospective cohort study was conducted using the PearlDiver Mariner Database, an all-payor claims database containing claims for over 53 million patients from 2010 to 2019 in all 50 US states. Rates and odds of all types of UECN were compared between 1:1:1 exact matched cohorts of obese patients who were medically managed, obese patients who underwent bariatric surgery, and nonobese patients (111,967 patients in each cohort). Results: Compared with nonobese patients, patients with obesity were significantly more likely to develop any UECN (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.09–1.18), carpal tunnel syndrome (OR, 1.15; 95% CI, 1.10–1.30), and 2 or more UECN (OR, 1.34; 95% CI, 1.20–1.48). Compared with obese patients who were managed medically, obese patients who underwent bariatric surgery were significantly less likely to develop any UECN (OR, 0.87; 95% CI, 0.84–0.91) and carpal tunnel syndrome (OR, 0.85; 95% CI, 0.81–0.89). Conclusions: Obese patients have higher odds of both single and concomitant UECN, specifically carpal tunnel syndrome, compared with nonobese patients. Bariatric surgery decreases the odds of developing UECN compared with obese patients not undergoing surgical intervention.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ansell, Stephen M. , Barnes, Jeffrey A. , Brammer, Jonathan E. , Clemens, Mark W. , Ghione, Paola , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shea, Lauren , Sokol, Lubomir , Wu, Peggy A. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, Hoppe, Richard T , Ghione, Paola , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Foss, Francine M. , Halwani, Ahmad , Kallam, Avyakta , Kim, Youn H , Kumar, Kiran Achut , Shinohara, Michi M. , Sokol, Lubomir , Torres‐Cabala, Carlos A. , Wilcox, Ryan A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 285-308

10.6004/jnccn.2022.0015 | PMID 35276674 Get It

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.
TFAM-dependent mitochondrial integrity in regulatory T cells preserves immune landscape and restrains inflammaging
Guo, Kai , Gill, Jappreet Singh, Debnath, Trishna , Bansal, Benu, Poojary, Rayansh, Correa, Jacquiline Kim, Celik, Hakan, Mehta, Het, Abrham, Eden, Even, Zachery, Rahman, Mansib, Costa, Abby Lund Da , Jain, Shilpi , Murugaiyan, Gopal , Ting, Adrian T. , Hur, Junguk , Brown‐Borg, Holly M. , Jurivich, Donald A. , Mathur, Ramkumar , Wang, Zhihan , Gill, Jappreet Singh, Bansal, Benu, Poojary, Rayansh, Correa, Jacquiline Kim, Celik, Hakan, Rahman, Mansib, Wang, Xusheng , Khan, Nadeem

Mayo Clinic

No container title available | March 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.03.08.483517 Get It

Abstract Foxp3⁺ regulatory T cells (Tregs) maintain immune homeostasis, yet the process that preserves their stability during aging remain unclear. Mechanistic progress has been hindered by models that ablate Tregs or delete Foxp3 , which induce acute autoimmunity and prevent longitudinal study of physiological regulatory drift. Here, we establish a dose-dependent mitochondrial framework that preserves Treg lineage survival while permitting gradual metabolic attenuation. Using Treg-restricted TFAM modulation, a complementary haploinsufficient model, and whole-spleen single-cell profiling. We identify lineage-selective immune remodeling characterized by contraction of naïve CD8⁺ and follicular B-cell pools, alteration of CD4⁺ states, expansion of activated Tregs, and emergence of neuroimmune stress linked transcriptional modules that parallel physiological aging. Mechanistically, mitochondrial insufficiency is associated with functional loss of FOXP3- centered chromatin coordination and enrichment of NF-κB/NFAT/AP-1 inflammatory and senescence programs while lineage identity remains detectable. Partial mitochondrial attenuation within Tregs alone is sufficient to drive chronic low-grade systemic inflammation, neuromuscular decline, gut microbial restructuring, and elevated microglial responsiveness without Treg depletion. Pharmacologic and microbiota-directed interventions partially reduce inflammatory tone and improve functional metrics. Together, our findings identify TFAM as a key regulator of immune aging and reveal that healthy mitochondrial function in Tregs is essential for protecting against inflammaging and age-associated functional decline.
Physical Therapy Combined With Subacromial Cortisone Injection Is a First‐Line Treatment Whereas Acromioplasty With Physical Therapy Is Best if Nonoperative Interventions Fail for the Management of Subacromial Impingement: A Systematic Review and Network M
Lavoie‐Gagne, Ophelie , Farah, Ghassan J. , Mehta, Nabil , Parvaresh, Kevin C. , Forsythe, Brian , Forsythe, Brian , Lu, Yining

Mayo Clinic

Arthroscopy | February 18, 2022 | Volume: 38 | Issue: 8 | Pages: 2511-2524

10.1016/j.arthro.2022.02.008 | PMID 35189304 Get It

Purpose To construct an algorithm to optimize clinical outcomes in subacromial impingement based on current, high‐level evidence. Methods A systematic review of all clinical trials on subacromial impingement published from 1999 to 2020 was performed. Demographic, clinical, range of motion (ROM), and patient‐reported outcome measure (PROM) data were collected. Interventions were compared via arm‐based Bayesian network meta‐analysis in a random‐effects model and treatments ranked via surface under the cumulative ranking curves with respect to 3 domains: pain, PROMs, and ROM. Results A total of 35 studies comprising 3,643 shoulders (42% female, age 50 ± 5 years) were included. Arthroscopic decompression with acromioplasty ranked much greater than arthroscopic decompression alone for pain relief and PROM improvement, but the difference in absolute PROMs was not statistically significant. Corticosteroid injection (CSI) alone demonstrated inferior outcomes across all 3 domains (pain, PROMs, and ROM) with low cumulative rankings. Physical therapy (PT) with CSI demonstrated moderate‐to‐excellent clinical improvement across all 3 domains whereas PT alone demonstrated excellent ROM and low‐moderate outcomes in pain and PROM domains. PT with nonsteroidal anti‐inflammatory drugs or alternative therapies ranked highly for PROM outcomes and moderate for pain and ROM domains. Finally, platelet‐rich plasma injections demonstrated moderate outcomes for pain, forward flexion, and abduction with very low‐ranking outcomes for PROMs and external rotation. Conclusions Arthroscopic decompression with acromioplasty and PT demonstrated superior outcomes whereas CSI demonstrated poor outcomes in all 3 domains (pain, PROMs, and ROM). For patients with significant symptoms, the authors recommend PT with CSI as a first‐line treatment, followed by acromioplasty and PT if conservative treatment fails. For patients with symptoms limited to 1 to 2 domains, the authors recommend a shared decision‐making approach focusing on treatment rankings within domains pertinent to individual patient symptomatology. Level of Evidence I, systematic review and network meta‐analysis of Level I studies.